-->

Company Registry

Aavogen Inc
Profile last edited on: 12/6/2019

Gene therapeutics for muscle wasting diseases
Year Founded
2015
First SBIR Year
2017
Latest SBIR Award
2019
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

13420 Glen Lea Way
Rockville, MD 20850
   (208) 596-9807
   N/A
   www.aavogen.com
Multiple Locations:   
Congressional District:   08
County:   Montgomery

Public Profile

AAVogen is a start-up biotechnology company organized around addressing the condition of muscle wasting - a consequence of a wide range of diseases and health conditions. Involving gene therapy, muscle biology, and regenerative medicine the firm is focused specifically on developing new treatments that benefit patients suffering from muscular dystrophy, heart failure, and other muscle diseases. The firm's primary focus is on AVGN7 is a viral gene therapeutic that blocks the inhibitory actions of myostatin, GDF11 and activin. In animal studies, its specificity for muscle and heart prevents their wasting without the dangerous side effects that have limited competing technologies. Founders and the firm are co-discoverers of AVGN7, which was developed through an academic collaboration with many talented and accomplished research partners. Their combined understanding of muscle biology, gene therapy and regenerative medicine is complemented by a Science Advisory Board with field-leading experts in muscle wasting diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2019 1 NIH $224,999
Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy
2019 2 NIH $1,867,192
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia

Key People / Management

  Buel "Dan" Rodgers -- Founder and CEO

  Heather Webb Hsu -- Chief Business Officer:

SBIR firms in the news

There are no news available.